-+ 0.00%
-+ 0.00%
-+ 0.00%

CORBUS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN TEMPO-1 REGISTRATIONAL STUDY OF CRB-701 IN PATIENTS WITH 2L+ OROPHARYNGEAL CANCER

路透·09/29/2026 12:00:07

请登录查看新闻详情